Increased natural killer cells and decreased CD3 +CD8 +CD62L + T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

British Journal of Haematology

Volumn 157, Issue 2, 2012, Pages 254-256

  Ohyashiki, Kazuma ^a   Katagiri, Sei Ichiro ^a   Tauchi, Tetsuzo ^a   Ohyashiki, Junko H ^a   Maeda, Yasuhiro ^b   Matsumura, Itaru ^b   Kyo, Tai Ichi ^c  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

Chronic myeloid leukaemia; NK cells; Stop imatinib

Indexed keywords

BCR ABL PROTEIN; CD3 ANTIGEN; CD8 ANTIGEN; IMATINIB; L SELECTIN;

ANTIGEN EXPRESSION; CANCER REGRESSION; CD3+ T LYMPHOCYTE; CD62L+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LETTER; NATURAL KILLER CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION;

ANTIGENS, CD3; ANTIGENS, CD8; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; KILLER CELLS, NATURAL; L-SELECTIN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE COUNT; MALE; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION;

EID: 84859218819     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08939.x     Document Type: Letter

References (7)

1. Deininger, M. (2011) Hematology: curing CML with imatinib - a dream come true? Nature Review in Oncology, 8, 127-128.
2. Mahon, F.-X., Réam, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J., Rousselot, P. & Intergroupe Français des Leucémies Myéloïdes Chroniques. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology, 11, 1029-1035.
3. Mustjoki, S., Ekblom, M., Arstil, T.P., Dybedal, I., Epling-Brunette, P.K., Guilhot, F., Hjorth-Hansen, H., Höglund, M., Kovanen, P., Laurinolli, T., Liesveld, J., Paquette, R., Pinilla-Ibarz, J., Rauhala, A., Shah, N., Simonsson, B., Sinisalo, M., Steegmann, J.L., Stenke, L. & Porkka, K. (2009) Clonal expansion of T-NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia, 23, 1398-1405.
4. Rohon, P., Porkka, K. & Mustjoki, S. (2010) Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. European Journal of Haematology, 85, 387-389.
5. Ross, D.M., Branford, S., Seymour, J.F., Schwarer, A.P., Arthur, C., Bartley, P.A., Slader, C., Field, C., Dang, P., Filshie, R.J., Mills, A.K., Grigg, A.P., Melo, J.V. & Hughes, T.P. (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 24, 1719-1724.
6. Sloma, I., Jiang, X., Eaves, A.C. & Eaves, C.J. (2010) Insights into the stem cells of chronic myeloid leukemia. Leukemia, 24, 1823-1833.
7. Usuki, K., Yokoyama, K., Nagamura-Inoue, T., Ito, A., Kida, M., Izutsu, K., Urabe, A. & Tojo, A. (2009) CD8+ memory T cells predominate over naïve T cells in therapy-free CML patients with sustained major molecular response. Leukemia Research, 33, e164-e165.